Pharmaceutical Pricing

We support a strong regulatory framework for pharmaceutical pricing and related assessment and negotiation processes which ensure value and deliver the best possible care for patients in a timely manner.

BMC Positions:
Submission to Finance Canada: Priorities for the 2024-25 Federal Budget (February 8, 2024)

Input to the PMPRB regarding development of new Guidelines (December 20, 2023)

Submission to the pan-Canadian Pharmaceutical Alliance: pCPA Temporary Access Process (pTAP) (August 16, 2023)

Submission to the Standing Committee on Health: Patented Medicine Prices Review Board (April 25, 2023)

PMPRB 2022 Draft Guidelines Consultation (December 5, 2022)

Federal Health Mandate: Put patient values, needs and improved outcomes at the centre of health and pharmaceutical policy (November 15, 2021)

Input to PMPRB Regarding Proposed Guideline Revisions Related to Gap Medicines, Comparator Countries and International Price Tests (August 31, 2021)

Input Regarding PMPRB Proposed Guideline Monitoring and Evaluation Plan (June 21, 2021)

Letter Responding to PMPRB Board Chair (June 8, 2021) (français)

Letter to the Prime Minister Regarding PMPRB (May 28, 2021) (français)

Submission to the Standing Committee on Health: PMPRB Guidelines (November 6, 2020) (français)

Letter to the Minister of Health (August 10, 2020) (français)

Submission Regarding PMPRB Revised Draft Guidelines (August 2020) (français)

Letter to the Minister of Health (June 19, 2020) (français)

Submission to the House of Commons Standing Committee on Health (May 2020)

Submission Regarding Draft Guidelines to Implement the Patented Medicines Regulations, as amended (February 2020)

Letter to Health Canada Regarding Proposed Patented Medicines Regulations (February 2018)

Submission Regarding PMPRB Modernization (October 2016)

Go to the top